CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as gefitinib emerged as an accepted treatment in second-or third-line setting in NSCLC. However, clinical surrogate markers of EGFR-TKI activity in NSCLC patients remain to be identified and we studied the prognostic value of CYFRA 21-1 in this setting. Serum samples from 53 patients with NSCLC receiving gefitinib after failure of at least a platinum-containing regimen were prospectively collected from January 2002 to December 2003. Multivariate analysis demonstrated an independent negative impact on survival for a level of CYFRA 21-1 higher than 3.5 ng ml À1 (HR ¼ 2.45, 95% CI 1.13 -5.29; P ¼ 0.02). In conclusion, CYFRA 21-1 is a tool available to predict the survival of NSCLC patients receiving gefitinib as third-line therapy in an independent manner. In case of a CYFRA 21-1 level higher than 3.5 ng ml À1 , treatment with gefitinib needs further evaluation giving its relative poor effect on survival.

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

“…Univariate and multivariate analyses demonstrated that CYFRA 21-1 levels higher than 3.3 ng/ ml had an independent negative impact on PFS (HR=1.93, 95% CI 1.09-3.44; P=0.025) and OS (HR=2.76, 95% CI 1.38-5.53; P=0.0004). Therefore, CYFRA 21-1 is an independent marker for poor prognosis in NSCLC patients receiving an EGFR TKI, which is consistent with a previous study (12).…”

“…Several (6)(7)(8)(9)(10). According to recent reports, CEA and CYFRA 21-1 were significant predictors of sensitivity and survival in patients treated with gefitinib (11)(12)(13). Therefore, we investigated the clinical significance of the pre-treatment serum levels of CEA and CYFRA 21-1 in advanced NSCLC patients who were treated with gefitinib or erlotinib.…”

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation

“…Clinical stage was evaluated by computed tomography (CT) scan of the chest and abdomen, emission computed tomography, skull magnetic resonance imaging and positron emission tomography-CT if possible, as recommended by Union for International Cancer Control (UICC) staging guidelines. 13 MPE was retrospectively confirmed by cytopathological analysis of pleural effusion.…”

Research Progress in Applying Proteomics Technology to Explore Early Diagnosis Biomarkers of Breast Cancer, Lung Cancer and Ovarian Cancer

“…Washam et al (2011) (Kulpa, et al, 1999;Molina, et al, 2003;Molina, et al, 2005;Holdenrieder, et al, 2004;Ardizzoni, et al, 2006) Barak, et al, 2004) (Hatzakis, et al, 2002;Muley, et al, 2002;Barlési, et al, 2004) Kashiwabara , et al, 2000;Pujol, et al, 2001;Hatzakis, et al, 2002;Reinmuth, et al, 2002;Kulpa, et al, 2002;Merle, et al, 2003;Vollmer, et al, 2003;Pujol, et al, 2003;Pujol, et al, 2004;Barlesi, et al, 2005 (Bonner, et al, 2000;Shibayama, et al, 2001;Satoh, et al, 2002;Massacesi, et al, 2002;Molina, et al, 2003;Muley, et al, 2004;Molina, et al, 2004;Schneider, et al, 2006) …”